Alpha-2B adrenergic receptor mediated hemodynamic profile of etomidate.
When used for tracheal intubation, etomidate does not effectively blunt the sympathetic response to laryngoscopy, unless combined with a potent opioid analgesic (1). In addition, a study found no clinically significant hemodynamic changes after etomidate administration in children supporting the clinical impression that etomidate is also safe in this population (4), although there is inadequate data to make dosage recommendations for induction of anesthesia in pediatric patients below the age of ten years; therefore, such use is not recommended (5).
Etomidate is also known for its neuroprotective properties. Etomidate has been used successfully for both induction and maintenance of anesthesia for neurosurgery (1). Nevertheless, due to its well-known inhibitory effect on adrenocortical synthetic function (6), its clinical usefulness for long-term treatment of elevated intracerebral pressure (ICP) is limited. The inhibition on corticosteroids synthesis is a widely recognized effect that may persist for 5 to 8 hours after a single dose of induction (1). In addition, the Institute for Safe Medications Practices has classified etomidate as a high risk medication and has heightened the risk of causing significant patient harm when used in error.
Etomidate is widely used because it causes minimal cardiorespiratory depression even in the presence of cardiovascular and pulmonary disease (7). The drug does not induce histamine release and can be safely used in patients with reactive airway disease. Consequently, etomidate is considered to be the induction agent of choice for poor-risk patients with cardiorespiratory disease, as well as in those situations in which preservation of a normal blood pressure is crucial (e.g., cerebrovascular disease) (1).
Regarding these properties, it is important to emphasize that, in spite of its side effect profile, etomidate still remains a valuable induction drug for specific indications (in patients with severe cardiovascular and cerebrovascular disease) (1). Little is known about the mechanism responsible of its cardiovascular effects. Our review will focus in describing how the interaction with the [alpha]-2B adrenergic receptors may account for its properties and how this interaction may produce a predictably different cardiovascular profile in specific clinical situations.
Mechanisms of Etomidate
In humans, the anesthetic effect of etomidate is thought to be mediated primarily through an action on gamma-aminobutyric acid type A (GABAA) receptors (8-9) Effects on different GABAa receptor subtypes are related to specific actions. Data available for etomidate point to [beta]-3-containing GABAA receptors mediating immobility and respiratory depression, in part hypnosis and, to a minor degree, hypothermia, while [beta]-2-containing GABAA receptors mediate, for the most part, hypothermia, and in a lesser degree hypnosis and sedation (10).
Etomidate also has a known inhibitory effect on adrenocortical synthetic function (11), which is mediated by inhibition of the activity of 11-[beta]-hydroxylase, an enzyme necessary for the synthesis of cortisol, aldosterone, 17-hydroxyprogesterone, and corticosterone (12). A single induction dose of etomidate produces an adrenal suppression that persists for 5 to 8 hours (1). It is speculated that this effect is responsible for the increased mortality in critically ill patients sedated with an etomidate infusion (1). Another study showed that a singledose etomidate for RSI in severely injured trauma patients is associated with increased Adult Respiratory Distress Syndrome (ARDS) and multiple organ dysfunction syndrome, in part, because of the effect of etomidate on the inflammatory response (13). Etomidate has been also shown to inhibit platelet function, resulting in prolongation of the bleeding time (14). Most studies agree that the sedative properties of etomidate are mediated by alpha-2 and GABAa receptors (8-9), but when we turn our look to evaluate the mechanism responsible of the hemodynamic stability associated with etomidate, the information is not as conclusive.
A study showed that etomidate increases the responsiveness to norepinephrine in an endothelium-dependent way, which is partially independent of the action of nitric oxide (NO), endothelium-derived hyperpolarizing factor (EDHF), cyclooxygenase products, lipooxygenase products, angiotension-II and Endothelin (15). It was also established that endothelium denuded arteries have a decreased contractile response to norepinephrine, which is mediated by a low intracellular calcium and a decreased calcium sensitivity of the myofilaments in the vascular smooth muscle cells (15). Regarding a calcium-related mechanism, etomidate inhibited angiotensin (AT) II-induced Ca[2.sup.++] mobilization in cultured rat aortic smooth muscle cells (15).
On the other hand, etomidate (5-300 uM) inhibited the vasodilator response to endothelium-derived nitric oxide (EDNO) or endothelium-derived hyperpolarizing factor (EDHF) in isolated human renal arteries (15). EDHF is thought to be a cytochrome P450-derived arachidonic acid metabolite that hyperpolarizes vascular smooth muscle cells by opening [Ca.sup.2++] -activated Potassium sup + channels (K sup [+.sub.Ca] channels). Etomidate inhibits the EDHF-mediated relaxant response to acetylcholine in the human renal artery, an effect that appears to be attributable to the cytochrome P450-inhibiting properties of this anesthetic (16).
Other studies have shown a critical role for potassium-ATP (KATP) channels. In vascular smooth muscles, opening of KATP channels leads to membrane hyperpolarization, resulting in muscle relaxation and vasodilation (17). Etomidate (1-100 uM) inhibited the vasodilator response to ATP-sensitive K (KATP) channel openers in isolated canine pulmonary arteries and rat aortas and inhibited the activities of vascular KATP channels at clinical concentrations (18).
Interactions of etomidate with second messenger systems such as the NO metabolism have been shown (19) and it has been found that alpha 2B-adrenoceptor subtype is involved in mediation of the antinociceptive action of nitrous oxide (20-21).
A new perspective focuses on the structural similarity between carboxylated imidazole etomidate and specific alpha 2-adrenoceptor agonists that belong to the class of imidazole compounds, such as clonidine and dexmedetomidine (22-23).
The following figure shows the structure of Etomidate and Dexmedetomidine (24):
[FIGURE 1 OMITTED]
These receptors are located primarily on presynaptic nerve endings and on other cells, such as the fi cell of the pancreas, and control adrenergic neuromediator and insulin output, respectively. When a sympathetic adrenergic nerve is stimulated, the released norepinephrine traverses the synaptic cleft and interacts with the (alpha-1 receptor). The stimulation of the alpha-2 receptor causes feedback inhibition of the ongoing release of norepinephrine from the stimulated adrenergic neuron. This inhibitory action decreases further output from the adrenergic neuron and serves as a local modulating mechanism for reducing sympathetic neuromediator output when there is high sympathetic activity. In contrast to alpha-1 receptors, the effects of binding at alpha-2 receptors are mediated by inhibition of adenylyl cyclase and a fall in the levels of intracellular cAMP (25). Three subtypes of alpha-2-adrenoceptors, termed alpha-2A, alpha-2B, and alpha-2C, have been cloned from several species including mice and humans (26-27). Alpha 2-receptor subtypes are encoded by distinct genes which are localized on separate chromosomes (24) and have been characterized pharmacologically and by cloning their cDNAs (28).
Alpha 2A-adrenoceptor subtype has been reported to be the predominant subtype involved in the antinociceptive, sedative, hypotensive, hypothermic, and behavioral actions of alpha-2 adrenoceptor agonists (29-32). Antinociceptive response to an exogenous alpha-2 agonist is mediated by an alpha-2A adrenoceptor (20). A study found that (32-adrenoceptors sensitizes [alpha]2A-adrenoceptors to desensitization after chronic epinephrine treatment (33). In the central nervous system, the alpha-2A subtype is the most prevalent and ubiquitous of the three, whereas alpha-2B is only present in a few discrete sites, principally the thalamic nuclei, and then in very small amounts (20).
Stimulation of alpha 2B-adrenoceptors in vascular smooth muscle leads to vasoconstriction, which causes the initial hypertension after administration of alpha 2-adrenoceptor agonists (22). In addition, the alpha-2B-adrenoceptor subtype is involved in mediation of the antinociceptive action of nitrous oxide (20-21). A polymorphism of the alpha-2B AR gene with three glutamic acids deleted from a glutamic acid repeat element (GluX12, amino acids 297-309) in the putative third intracellular loop of the receptor protein was identified (34- 35), and obese patients with the mutation in both alleles were found to have a lower basal metabolic rate (BMR) (34). Heart rate variability is also influenced by these receptors. A study showed that, carriers of Short/Short (both alleles with the three glutamic acids deleted, see above) had significantly greater low frequency and very low frequency than Long/Long carriers, as well as a higher sympathetic nervous system index (36). Another study found that non-diabetic carriers of a polymorphism of the alpha2B receptor (three glutamic acids deleted at position 297-299) have increased predisposition to Arterial Hypertension. The mechanism involved appears to be impaired agonist induced desensitization (37).
Alpha 2C-receptor has been shown to modulate dopaminergic neurotransmission, various behavioral responses, and to induce hypothermia (38-39). In addition, this subtype contributes to spinal antinociception of the imidazoline moxonidine in mice (40).
Etomidate and alpha-2B receptors
Several studies have provided evidence regarding the hemodynamic stability associated with etomidate and its capacity to stimulate alpha-2B receptors based on its structural similarity with alpha-2 agonists. The current information is that mice and animals lacking functional alpha-2A receptors show no difference with controls regarding their capacity to be sedated/hypnotized, suggesting that alpha-2A receptors appear to be unnecessary for etomidate to produce sedation/hypnosis. In addition, it is known that etomidate has higher affinity for alpha-2B and alpha-2C receptors than alpha-2A receptors (24). Disruption of the alpha-2C adrenoceptor subtype does not lead to hemodynamic effects (22). However, alpha-2C-receptors operate together with alpha-2A receptors as presynaptic inhibitory regulators of sympathetic norepinephrine release (41). In a study using wild-type mice and mice lacking alpha2A or alpha-2B receptors, a rapid intravenous injection of dexmedetomidine resulted in a transient hypertension in wild-type mice that was followed by a long-lasting hypotension. Deletion of the alpha-2A receptor disrupted the hypotensive response, whereas the initial hypertension was absent in alpha2B-deficient animals (22).
Administration of dexmedetomidine in mice lacking both alpha-2A and alpha-2B receptors, failed to produce the initial hypertension, which can be attributed to the alpha-2B adrenoceptor subtype (33) and the central hypotensive effect related to the alpha-2A adrenoceptor subtype (30). These findings are consistent with the observation that activation of presynaptic sympathetic alpha- 2C receptors can decrease norepinephrine release (41).
Other authors have also described this biphasic response to the intravenous response of an alpha-2 agonist (22). They described an initial phase in which mean arterial pressure rises transiently as arterial alpha-2 AR constrict vascular smooth muscle (42) and that, after this initial hypertensive response, mean arterial pressure drops below baseline because alpha-2 AR in the ventrolateral medulla oblongata attenuate symphathetic and accentuate parasymptathetic outflow (43). Considering that central hypotensive response is not mediated by alpha 2B or C receptors, they conclude that alpha-2A subtype is important in the control of the central sympathetic outflow (22).
Although this initial view seems to support the concept that the early hypertensive response is mediated by alpha-2B receptors, subsequent hypotensive response is mediated by alpha-2A receptors and no important role for alpha-2C is seen in mediating hemodynamic changes. It is important to take into consideration that alpha-2B subtype receptors are found primarily in the brain, liver, lung and kidney, with the highest amounts in the kidney. The fact that this response is observed rapidly, arises doubts concerning the role of alpha-2B receptors in the kidney, although evidence of a relation with the hypertensive response observed after salt loading has been described (44).
Considering that evidence supporting that hemodynamic changes observed during the induction with etomidate are grossly due to the agonist effect on alpha-2 receptors, we inquired about the effects that could produce abnormal functioning or availability of alpha-2 receptors in the hemodynamic response to etomidate.
Focusing on the initial hypertensive response mediated primarily by peripheral alpha-2B receptors, we found some information regarding abnormal states of functioning of these receptors. It is known that all these receptors (alpha-2) couple to the inhibitory heterotrimeric GTP-binding protein (Gi) and inhibit adenyl cyclase (22). A polymorphism of alpha-2B adrenergioreceptor consisting of a deletion of three glutamic acids (residues 301-303) from a glutamic acid repeat element in the third intracellular loop has been associated to a small decrease in the coupling efficiency, resulting in reduced inhibition of adenylyl cyclase (45), with a reduced basal metabolic rate in obese subjects, with an increase in body weight among nondiabetic subjects, and modulation of autonomic nervous function in nondiabetic men (45). Normal alpha-2B receptors undergo term agonist promoted desensitization which involves phosphorylation of the receptor that ultimately produces uncoupling of the receptor with its Gi effector protein. Initial phosphorylation is mediated by a G protein-coupled receptor kinase (GRK) member of the serine/threonine kinase family. This enzyme requires the presence of acidic residues (mainly Glutamic Acid residues) in the third intracellular loop of the receptor and the deletion of these residues (polymorphic variant of the alpha-2B receptor described above) produce a deficiency in the functioning of the phosphorylating enzyme and a defective phosphorylation of the receptor and, consequently, decreased desensitization. Desensitization may also limit the therapeutic effectiveness of administered agonists (44). Different allele frequencies for this polymorphism have been established between racial groups, being more common in Caucasians (allele frequency 0.31) than in African Americans (allele frequency 0.12) (45). This polymorphism has also been associated to higher predisposition to essential arterial hypertension in Swedes (37), in which the mechanism presumably is impaired agonist desensitization. Little is available about etomidate (as an alpha-2 agonist) producing marked hypertensive effects and/or a more pronounced response in carriers of this polymorphism. The association of the a2B-AR genotype with either hypertension and coronary events or BMR and obesity needs to be tested in other well-designed genetic studies (46).
(1.) Barash PG, Cullen BF, Stoelting RK. Clinical Anesthesia, 5th Ed; Philadelphia; Lippincott Williams & Wilkins, 2006: p. 344-345.
(2.) Doenicke A. Etomidate, a new intravenous hypnotic. Acta Anaesthesiol Belg 1974;25:307-315.
(3.) Wolfson AB. Harwood-Nuss' Clinical Practice of Emergency Medicine, 4th Ed; Portland; Lippincott Williams & Wilins, 2005: p. 1150-1153.
(4.) Sarkar M. Hemodynamic Responses to Etomidate on Induction of Anesthesia in Pediatric Patients. Anesth Analg 2005;101:645-650.
(5.) Amidate (etomidate) [Package Insert]. North Chicago (IL): Abbott Laboratories; 1998.
(6.) White PF, Kan PB, Wagner RL, et al. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984;310:1415, 1984.
(7.) Weng JT, Smith RA, Gooding JM, et al. Cardiovascular and pulmonary response following etomidate induction of anesthesia in patients with demonstrated cardiac disease. Anesth Analg 1979;50:40.
(8.) Pistis M, Peters JA, Lambert JJ, Belelli D. The interaction of general anaesthetics and neurosteroids with GABA(A) and glycine receptors. Neurochem Int 1999;34:447-455.
(9.) Knauer CS, Granja R, Moody EJ, et al. Distinct structural requirements for the direct and indirect actions of the anaesthetic etomidate at GABA(A) receptors. Toxicol Lett 1998;101:209-215.
(10.) Zeller A, Arras M, Lazaris A, Jurd R, Rudolph U. Distinct molecular targets for the central respiratory and cardiac actions of the general anesthetics etomidate and propofol. FASEB J 2005;19:1677-1680.
(11.) White PF, Kan PB, Wagner RL, et al. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984;310:1415.
(12.) White PF, Wagner RL. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984;61:647.
(13.) Cuschieri J, Jurkovich GJ, Warner KJ, et al. Single-dose etomidate for rapid sequence intubation may impact outcome after severe injury. J Trauma 2009;67:45-50.
(14.) Weis S, Herr A, Gries A, et al. Etomidate and thiopental inhibit platelet function in patients undergoing infrainguinal vascular surgery. Acta Anaesthesiol Scand 2001;45:449-457.
(15.) Shirozu K. The Mechanisms of the Direct Action of Etomidate on Vascular Reactivity in Rat Mesenteric Resistance Arteries. Anesth Analg 2009;108:496-507.
(16.) Kessler P, Lischke V, Hecker M. Etomidate and Thiopental Inhibit the Release of Endothelium-derived Hyperpolarizing Factor in the Human Renal Artery. Anesthesiology 1996;84:1485-1486.
(17.) Maier-Rudolph W, von Beckerath N, Mehrke G, Gunther K, Goedel-Meinen Daut J. Hypoxic dilation of coronary arteries is mediated by ATPsensitive potassium channels. Science 1990;247:1341-1344.
(18.) Kawahito S, Kawano T, Nakamura A. Differential Effects of Etomidate and Midazolam on Vascular Adenosine Triphosphate-sensitive Potassium Channel. Anesthesiology 2007;106:515-522.
(19.) Scholz J, Suppe E, Schulte AM, Esch J, Tonner PH. L-nitroargininemethylester (L-NAME), a nitric oxide synthase inhibitor, increases the anesthetic potency of etomidate. Anasthesiol Intensivmed Notfallmed Schmerzther 1999;34:136-139.
(20.) Guo TZ, Davies MF, Kingery WS, Patterson AJ, Limbird LE, Maze M. Nitrous oxide produces antinociceptive response via alpha-2B and/or alpha-2C adrenoceptor subtypes in mice. Anesthesiology 1999;90:470-476.
(21.) Kingery WS, Davies MF, Agashe GS, Clark JD, Kobilka BK, Hashimoto T, Maze M, Sawamura S. Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of alpha-2B adrenoceptors. J Neurosci 2000;20:9242-9251.
(22.) Desai K, Hein L, Link RE. Cardiovascular regulation in mice lacking alpha 2-adrenergic receptor subtypes b and c. Science 1996;273:803-805.
(23.) Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, Kobilka BK, Hein L. Abnormal regulation of the sympathetic nervous system in alpha 2A-adrenergic receptor knockout mice. Mol Pharmacol 1999;56:154-161.
(24.) Philipp M, Tonner PH, Paris A. Activation of alpha-2B Adrenoceptors Mediates the Cardiovascular Effects of Etomidate. Anesthesiology 2003;99:889-895.
(25.) Mycek MJ, Harvey RA, Champe PC. Lippincott's Illustrated reviews: Pharmacology, Chapter 6, 2nd ed, Philadelphia, Unied States, Lippincott Williams and Wilkins, 2000: p. 57-59
(26.) Matsui H, Kobilka TS, Kobilka BK. Cloning, sequencing, and expression of the gene coding for the human platelet alpha-2-adrenergic receptor. Science 1987;238:650-656.
(27.) Kobilka TS, Yang-Feng TL, Regan JW, et al. Cloning and expression of a human kidney cDNA for an alpha-2 adrenergic receptor subtype. Proc Natl Acad Sci USA 1988;85:6301-6305.
(28.) Hein L. Alpha2-adrenoceptor subtypes-surprising insights from gene-targeted mouse models. Auton Autacoid Pharmaco 2003;23:234-235.
(29.) MacMillan LB, Guo TZ, Lakhlani PP. Substitution of a mutant alpha-2A adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic- sparing responses in vivo. Proc Natl Acad Sci USA 1997;94:9950-9955.
(30.) Hein L, Smith MS, MacMillan LB, et al. Central hypotensive effects of the alpha-2A adrenergic receptor subtype. Science 1996;273:801-803.
(31.) Eikenberg DC, Hieble JP, Bylund DB, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46:121-136.
(32.) Fontana DJ, Hedley LR, Hunter JC, et al. Assessment of the role of alpha-2 adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br J Pharmacol 1997;122:1339-1344.
(33.) Altememi GF, Mandyam CD, Bawa-Khalfe T. The presence of (32 adrenoceptors sensitizes [alpha]2A-adrenoceptors to desensitization after chronic epinephrine treatment. BMC Pharmacology 2007;7:16.
(34.) Koulu M, Pesonen U, Heinonen P, et al. Identification of a three-amino acid deletion in the alpha-2B adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. J Clin Endocrinol Metab 2006;84:2429-2433.
(35.) Baldwin CT, Schwartz F, Baima J, Burzstyn M, DeStefano AL, Gavras I, et al. Identification of a polymorphic glutamic acid stretch in the alpha-2B-adrenergic receptor and lack of linkage with essential hypertension. Am J Hypertens 1999;12:853-857.
(36.) Matsunaga T, Nagasumi K, Naoko Suzuki, et al. Alpha 2B-Adrenergic Receptor Deletion Polymorphism Associates with Autonomic Nervous System Activity in Young Healthy Japanese. J Clin Endocrinol Metab 2003;88:1184-1187.
(37.) von Wowern F, Bengtsson K, Lindblad U, et al. A functional polymorphism in the alpha-2B adrenergic receptor gene, a positional candidate gene on chromosome 2, is associated with hypertension in Swedes. Am J Hypertens-Supp 2004;22:54.
(38.) Sallinen J, Haapalinna A,Scheinin M. Evaluation of the alpha 2C-adrenoceptor as a neuropsychiatric drug target studies in transgenic mouse models. Life Sci 2001;68:2277-2285.
(39.) Link RE, Haapalinna A, Sallinen J, et al. Genetic alteration of alpha 2C-adrenoceptor expression in mice: Influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtypenonselective alpha 2-adrenoceptor agonist. Mol Pharmacol 1997;51:36-46.
(40.) Stone LS, Kitto KF, Fairbanks CA, et al. Alpha 2C-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol 2002;300:282-290.
(41.) Altman JD, Kobilka BK, Hein L. Two functionally distinct alpha 2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999;402:181-184.
(42.) Ward DS, Belleville JP, Maze M, Bloor BC. Effects of Intravenous Dex medetomidine in Humans: II. Hemodynamic Changes. Anesthesiology 1992;77:1134-1142.
(43.) Ruffolo RR Jr, Nichols AJ, Stadel JM, Hieble JP, et al. Pharmacologic and Therapeutic Applications of alpha2-Adrenoceptor Subtypes. Annu. Rev. Pharmacol. Toxicol 1993;33:243-279.
(44.) Brown KM, Forbes SL, Small KM, et al. Polymorphic deletion of three intracellular acidic residues of the alpha 2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated phosphorylation and desensitization. J Biol Chem 2001;276:4917-4922.
(45.) Buzas B, Hipp H, Belfer I, et al. Haplotype-based analysis of alpha 2A, 2B, and 2C adrenergic receptor genes captures information on common functional loci at each gene. J Hum Genet 2005;50:12-20.
(46.) Large V. Alpha-2B adrenergic receptor and genetic variant. Clin Auton Res 2003;13:173-174.
Osmar Creagh, MD *; Hector Torres, MD [[dagger]]; Normidaris Rodriguez, MD *; Sebastian Rodrigo Gatica, MD [[double dagger]]
* Resident Anesthesiology UPR MSC, [[dagger]] Faculty Department of Anesthesiology UPR MSC, [[double dagger]] Research Fellow Department of Anesthesiology UPR MSC
Address correspondence to: Sebastian R. Gatica Moris, Department of Anesthesiology University of Puerto Rico Medical Sciences Campus, A-989 Main Building, PO Box 365067, San Juan, PR 00936-5067. Tel: (787) 758-2525 ext. 1920/1921, (787) 7580640, (787)766-2844 * Fax: (787) 758-1327 * Email: email@example.com
|Printer friendly Cite/link Email Feedback|
|Author:||Creagh, Osmar; Torres, Hector; Rodriguez, Normidaris; Gatica, Sebastian Rodrigo|
|Publication:||Puerto Rico Health Sciences Journal|
|Article Type:||Perspectiva general de la droga|
|Date:||Jun 1, 2010|
|Previous Article:||Testing of anti-atherogenic drugs and food components on cell cultures: assessment of reliability.|
|Next Article:||Knowledge and implementation of the DNR in Internal Medicine teaching programs.|